ArticleTremor and other hyperkinetic movements (New York, N.Y.)2025
Postmortem Analysis 35 Months after Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for Essential Tremor.
Article in Tremor and other hyperkinetic movements (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is an emerging, non-invasive treatment for essential tremor (ET). However, postmortem data on the long-term neuropathological effects are limited. Case report: An 86-year-old man with refractory ET underwent MRgFUS thalamotomy. Tremor improved by 95% and remained controlled until his death 35 months later. Postmortem MRI and neuropathologic analysis showed localized disruption of the dentatorubrothalamic tract and demyelination near the treatment site with preserved neuronal integrity. Discussion: This is the first postmortem analysis of MRgFUS thalamotomy 35 months after procedure. Findings confirm sustained tremor relief associated with selective demyelination. The lesion remained well-defined without expansion, supporting MRgFUS as a precise and safe treatment for ET. Highlights: This paper presents the first long-term (35-month) postmortem analysis of MRgFUS thalamotomy demonstrating sustained clinical efficacy. Postmortem MRI confirmed that the lesion remained localized to the original thalamotomy site, with focal disruption of the dentatorubrothalamic tract. Neuropathological examination revealed selective demyelination in the posterior thalamus near the treatment site, without evidence of neuronal loss. These findings support the long-term safety, precision, and durability of MRgFUS as a non-invasive therapeutic option for essential tremor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.